1 Guidance

1 Guidance

This guidance replaces NICE technology appraisal guidance 110 issued in September 2006. For details see 'About this guidance'.

1.1 Rituximab, in combination with:

  • cyclophosphamide, vincristine and prednisolone (CVP)

  • cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)

  • mitoxantrone, chlorambucil and prednisolone (MCP)

  • cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-╬▒ (CHVPi) or

  • chlorambucil

    is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people.

  • National Institute for Health and Care Excellence (NICE)